We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+81.75%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$99.4M
AUM Growth
-$24.1M
Cap. Flow
-$19.6M
Cap. Flow %
-19.71%
Top 10 Hldgs %
60.37%
Holding
49
New
8
Increased
12
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
DRUG
Bright Minds Biosciences
DRUG
+$2.43M
2
TRVI icon
Trevi Therapeutics
TRVI
+$1.54M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.35M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.06M
5
ZYME icon
Zymeworks
ZYME
+$940K

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$8.98M
2
ACLX
Arcellx
ACLX
+$4.44M
3
KURA icon
Kura Oncology
KURA
+$3.85M
4
TSHA icon
Taysha Gene Therapies
TSHA
+$2.56M
5
CMPS
Compass Pathways
CMPS
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
Zymeworks
ZYME
$1.72B
$984K 0.99%
+67,240
New +$940K
ELDN icon
27
Eledon Pharmaceuticals
ELDN
$265M
$971K 0.98%
+235,750
New +$929K
VERV
28
DELISTED
Verve Therapeutics
VERV
$904K 0.91%
160,200
+14,100
+10% +$79.5K
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$2.52B
$883K 0.89%
21,000
-4,100
-16% -$203K
GILD icon
30
Gilead Sciences
GILD
$160B
$845K 0.85%
9,150
-10,350
-53% -$932K
ACLX
31
DELISTED
Arcellx
ACLX
$824K 0.83%
10,743
-51,357
-83% -$4.44M
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$755K 0.76%
+740,000
New +$1.35M
THRD
33
DELISTED
Third Harmonic Bio
THRD
$512K 0.52%
49,800
+34,292
+221% +$427K
ARTV
34
Artiva Biotherapeutics
ARTV
$564M
$444K 0.45%
44,000
– –
FBRX icon
35
Forte Biosciences
FBRX
$1.57B
$412K 0.41%
+18,139
New +$216K
CRVS icon
36
Corvus Pharmaceuticals
CRVS
$1.16B
$398K 0.4%
+74,307
New +$555K
CELC icon
37
Celcuity
CELC
$4.52B
$327K 0.33%
25,000
-21,600
-46% -$305K
RAPP
38
Rapport Therapeutics
RAPP
$2.12B
$291K 0.29%
16,400
-1,200
-7% -$26.6K
NUVB.WS
39
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$20.9K 0.02%
90,832
– –
BNTC icon
40
Benitec Biopharma
BNTC
$453M
– –
-29,800
Closed -$274K
CMPS
41
Compass Pathways
CMPS
$1.82B
– –
-386,500
Closed -$2.43M
CRBP icon
42
Corbus Pharmaceuticals
CRBP
$180M
– –
-18,500
Closed -$382K
DYN icon
43
Dyne Therapeutics
DYN
$4.82B
– –
-46,200
Closed -$1.66M
GERN icon
44
Geron
GERN
$1.01B
– –
-154,900
Closed -$703K
KURA icon
45
Kura Oncology
KURA
$830M
– –
-197,000
Closed -$3.85M
CYPH
46
Cypherpunk Technologies Inc
CYPH
$72.6M
– –
-120,500
Closed -$310K
SLRN
47
DELISTED
ACELYRIN
SLRN
– –
-364,000
Closed -$1.79M
TVTX icon
48
Travere Therapeutics
TVTX
$6.05B
– –
-19,000
Closed -$266K
CLYM
49
Climb Bio
CLYM
$766M
– –
-54,000
Closed -$275K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Acuta Capital Partners held 49 positions worth $99.4M, down 19% from $123M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners withdrew a net $19.6M in Q4 2024, closing 10 positions and reducing 15 holdings. Its most notable exit was Kura Oncology, an estimated $3.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Bright Minds Biosciences worth $2.49M.

  • Acuta Capital Partners's largest Q4 2024 buy was Bright Minds Biosciences: 69,124 shares worth $2.49M.
  • Acuta Capital Partners added most to Trevi Therapeutics in Q4 2024, an estimated $1.54M increase.
  • Acuta Capital Partners's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $8.98M.
  • Acuta Capital Partners fully exited Kura Oncology in Q4 2024, selling an estimated $3.85M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $99.4M portfolio in Q4 2024.
  • Acuta Capital Partners opened 8 new positions and closed 10 in Q4 2024.
  • Acuta Capital Partners's portfolio value fell 19% quarter-over-quarter to $99.4M.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.